We want to share the acknowledgment that APICES has received in the recent publication titled “Open-label phase II clinical trial of ketoconazole as CYP17 inhibitor in metastatic or advanced non-resectable granulosa cell ovarian tumors: the GREKO (Granulosa Et Ketoconazole) trial, GETHI 2011-03”. published in Clinical and Translational Oncology in which APICES has collaborated in project design, setup, coordination and project management and data management. This means an extra motivation to all APICES team in order to give continuity to the implication we have in every project in which we collaborate. APICES is very proud of the recognition of our work, and we would like to thank Spanish Group for Research in Orphan, Infrequent Tumors (GETHI) for giving us the opportunity to appear in the acknowledgements of the publication and congratulate them and all the investigators for their project success.
This study determine the efficacy and safety profile of ketoconazole in metastatic or locally advanced non-resectable granulosa cell ovarian cancer.
